NEW YORK (GenomeWeb) – Cambridge Isotope Laboratories and MRM Proteomics said yesterday that they have signed an exclusive global supply agreement for mass spec-based targeted proteomics assays.
Under the agreement, CIL will have exclusive selling rights to MRM Proteomics' PeptiQuant kits used for quantitative proteomics and will provide distribution for the products worldwide.
The most widely used mass spec approach for targeted protein quantitation, MRM-MS assays typically incorporate stable isotope labeled (SIL) peptides to improve their accuracy and reproducibility.
MRM Proteomics currently offers PeptiQuant kits for the measurement of 76 proteins associated with various diseases as well as for mass spec QC work. Under the agreement, the two companies plan to develop additional kits for specific disease areas and for quantitative metabolomics research.
"CIL is the world's leading producer and supplier of stable isotope enriched small molecules to the mass spectrometry community," MRM Proteomics CEO Gary Kruppa said in a statement. "CIL knows our market and customers already and has excellent sales and distribution channels worldwide."
Financial and other terms of the agreement were not disclosed.